STOCKHOLM, Sweden I September 16, 2015 I Findings from a head-to-head trial comparing Victoza® (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 diabetes.Results from the LIRA-LIXI trial were announced today in an oral presentation at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.
Read the full release with references in PDF
SOURCE: Novo Nordisk
Post Views: 77
STOCKHOLM, Sweden I September 16, 2015 I Findings from a head-to-head trial comparing Victoza® (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 diabetes.Results from the LIRA-LIXI trial were announced today in an oral presentation at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.
Read the full release with references in PDF
SOURCE: Novo Nordisk
Post Views: 77
